Journal Title：Nar Cancer

The original intention of the founding of Nar Cancer was to provide a high-level communication platform for scholars in the fields of nucleic acid research and cancer research, and to promote cooperation and integration between the two fields. The editor in chief, Professor William S. Dynan, comes from Emory University School of Medicine in the United States, which has laid a solid foundation for the academic orientation and development strategy of the journal. This journal mainly publishes original research, investigation, and summary articles in the interdisciplinary field of nucleic acid research and cancer research, covering cancer computational biology, cancer data resources, DNA damage sensing and repair, gene regulation and chromosome, genomics, methodology, nucleic acid based cancer therapy, and structural biology of cancer-related macromolecules. The publication of these contents not only enriches the theoretical system of cancer research, but also provides important references and guidance for clinical practice.

In summary, Nar Cancer is an academic journal with significant influence in the interdisciplinary field of nucleic acid research and cancer, providing a high-level communication platform for scholars worldwide and promoting cooperation and integration between the two fields.

《癌癥雜志》的創刊初衷是為核酸研究和癌癥研究領域的學者提供一個高水平的交流平臺，推動兩個領域間的合作與融合。其主編William S. Dynan教授來自美國埃默里大學醫學院，這一背景為雜志的學術導向和發展戰略奠定了堅實的基礎。該雜志主要發表核酸研究與癌癥研究交叉領域的原創研究、調查及總結性文章，涵蓋了癌癥計算生物學、癌癥數據資源、DNA損傷感應與修復、基因調控與染色體、基因組學、方法學、基于核酸的癌癥治療以及癌癥相關大分子的結構生物學等多個方面。這些內容的發表，不僅豐富了癌癥研究的理論體系，也為臨床實踐提供了重要的參考和指導。

總之《Nar Cancer》雜志是一本在核酸研究與癌癥領域交叉學科中具有重要影響力的學術期刊，為全球學者提供了一個高水平的交流平臺，推動了兩個領域間的合作與融合。

Nar Cancer由Oxford University Press出版商出版，收稿方向涵蓋Medicine - Oncology全領域，平均審稿速度 13 Weeks ，影響因子指數3.4，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。